Search | Clinical Trials Finder

Conditions: Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma, Recurrent Rectal Carcinoma, Stage IIA Rectal Cancer AJCC v7, Stage IIB Rectal Cancer AJCC v7, Stage IIC Rectal Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7
Interventions: Radiotherapy, Fluorouracil, Leucovorin Calcium, Oxaliplatin, Irinotecan; Radiation · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
Interventions: 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Trifluridine and Tipiracil Hydrochloride; Radiation · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma, Head and Neck Carcinoma, HER2/Neu Negative, Hormone-Resistant Prostate Cancer, Limited Stage Small Cell Lung Carcinoma, Myelodysplastic Syndrome, Progesterone Receptor Negative, Progressive Disease, Recurrent Carcinoma, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage IIA Pancreatic Cancer, Stage IIA Rectal Cancer, Stage IIB Pancreatic Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage III Colon Cancer, Stage III Esophageal Cancer, Stage III Gastric Cancer, Stage III Non-Small Cell Lung Cancer, Stage III Ovarian Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Skin Melanoma, Stage IIIA Colon Cancer, Stage IIIA Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Rectal Cancer, Stage IIIA Skin Melanoma, Stage IIIB Colon Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Rectal Cancer, Stage IIIB Skin Melanoma, Stage IIIC Colon Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Rectal Cancer, Stage IIIC Skin Melanoma, Stage IV Bladder Cancer, Stage IV Bone Sarcoma, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Ovarian Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IV Soft Tissue Sarcoma, Stage IVA Bone Sarcoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Bone Sarcoma, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Triple-Negative Breast Carcinoma
Interventions: Best Practice, Laboratory Biomarker Analysis, Supportive Care, Survey Administration; Other · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Fullerton, California

Conditions: Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions: cytology specimen collection procedure, laboratory biomarker analysis; Other
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Anal Canal Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage II Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8, Stage IIB Anal Cancer AJCC v8, Stage III Anal Cancer AJCC v8, Stage IIIA Anal Cancer AJCC v8, Stage IIIB Anal Cancer AJCC v8, Stage IIIC Anal Cancer AJCC v8
Interventions: Cisplatin, Fluorouracil, Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy, Quality-of-Life Assessment, Questionnaire Administration; Drug · Radiation · Procedure + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer Survivor, Healthy Subject, Stage I Colorectal Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIA Colorectal Cancer, Stage IIB Breast Cancer, Stage IIB Colorectal Cancer, Stage IIC Colorectal Cancer, Stage IIIA Breast Cancer, Stage IIIA Colorectal Cancer, Stage IIIB Breast Cancer, Stage IIIB Colorectal Cancer, Stage IIIC Breast Cancer, Stage IIIC Colorectal Cancer
Interventions: Educational Intervention, Internet-Based Intervention, Monitoring Device, Quality-of-Life Assessment, Questionnaire Administration; Other · Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 30 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer, Pain, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions: assessment of therapy complications, cognitive assessment, psychosocial assessment and care; Procedure
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 2,310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 32
States / cities: Chicago, Illinois • Evanston, Illinois • Elkhart, Indiana + 19 more

Conditions: Colorectal Cancer
Interventions: cetuximab, capecitabine, oxaliplatin, therapeutic surgical procedure, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 130
States / cities: Mobile, Alabama • Tucson, Arizona • Berkeley, California + 93 more

Conditions: Cancer
Interventions: protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy; Genetic · Other · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: Up to 120 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Colorectal Cancer, Hereditary Non-polyposis Colon Cancer
Interventions: counseling intervention, CD-ROM intervention; Other
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: Newark, Delaware • Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Healthy Subject, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Psychosocial Effects of Cancer and Its Treatment, Recurrent Bladder Cancer, Recurrent Cervical Cancer, Recurrent Colon Cancer, Recurrent Gastric Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Recurrent Uterine Sarcoma, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage II Bladder Cancer, Stage II Renal Cell Cancer, Stage II Urethral Cancer, Stage IIA Cervical Cancer, Stage IIA Colon Cancer, Stage IIA Gastric Cancer, Stage IIA Ovarian Epithelial Cancer, Stage IIA Ovarian Germ Cell Tumor, Stage IIA Pancreatic Cancer, Stage IIA Rectal Cancer, Stage IIA Uterine Sarcoma, Stage IIB Cervical Cancer, Stage IIB Colon Cancer, Stage IIB Gastric Cancer, Stage IIB Ovarian Epithelial Cancer, Stage IIB Ovarian Germ Cell Tumor, Stage IIB Pancreatic Cancer, Stage IIB Rectal Cancer, Stage IIB Uterine Sarcoma, Stage IIC Colon Cancer, Stage IIC Ovarian Epithelial Cancer, Stage IIC Ovarian Germ Cell Tumor, Stage IIC Rectal Cancer, Stage III Bladder Cancer, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage III Urethral Cancer, Stage IIIA Cervical Cancer, Stage IIIA Colon Cancer, Stage IIIA Gastric Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Rectal Cancer, Stage IIIA Uterine Sarcoma, Stage IIIB Cervical Cancer, Stage IIIB Colon Cancer, Stage IIIB Gastric Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Rectal Cancer, Stage IIIB Uterine Sarcoma, Stage IIIC Colon Cancer, Stage IIIC Gastric Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Rectal Cancer, Stage IIIC Uterine Sarcoma, Stage IV Bladder Cancer, Stage IV Gastric Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Stage IV Urethral Cancer, Stage IVA Cervical Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVA Uterine Sarcoma, Stage IVB Cervical Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Stage IVB Uterine Sarcoma, Ureter Cancer, Stage IIA Lung Carcinoma, Stage IIB Lung Carcinoma, Stage IIIA Lung Carcinoma, Stage IIIB Lung Carcinoma
Interventions: educational intervention, telephone-based intervention, quality-of-life assessment, questionnaire administration; Other · Behavioral · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Duarte, California

Conditions: Stage I Breast Cancer, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Prostate Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage II Colorectal Cancer AJCC v7, Stage II Prostate Cancer, Stage IIA Breast Cancer, Stage IIA Colorectal Cancer AJCC v7, Stage IIA Prostate Cancer, Stage IIB Breast Cancer, Stage IIB Colorectal Cancer AJCC v7, Stage IIB Prostate Cancer, Stage IIC Colorectal Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7
Interventions: Informational Intervention, Internet-Based Intervention, Quality-of-Life Assessment, Questionnaire Administration, Telephone-Based Intervention; Other · Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 30 Years and older
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 2
States / cities: New Brunswick, New Jersey • Philadelphia, Pennsylvania

Conditions: Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage IIB Anal Cancer AJCC v8, Stage III Anal Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Colonoscopy, Computed Tomography, Digital Rectal Examination, High Resolution Anoscopy, Magnetic Resonance Imaging, Nivolumab, Patient Observation, Proctoscopy, Sigmoidoscopy, X-Ray Imaging; Procedure · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 887
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 568 more

Conditions: Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer
Interventions: N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 35
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more

Conditions: Colorectal Cancers
Interventions: RENCA macrobeads; Biological
Lead sponsor: The Rogosin Institute; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 4
States / cities: Westwood, Kansas • New York, New York • The Bronx, New York + 1 more

Conditions: Lung Cancer, Tobacco Use Disorder, Breast Cancer, Colorectal Cancer, Prostate Cancer
Interventions: Nicotine Replacement Patch; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Colorectal Cancer, Dermatologic Complications, Lung Cancer, Therapy-related Toxicity
Interventions: assessment of therapy complications, psychosocial assessment and care, quality-of-life assessment; Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 113
States / cities: Tucson, Arizona • Castro Valley, California • Duarte, California + 78 more

Conditions: Depressive Symptoms, Fatigue, Psychosocial Effects of Cancer and Its Treatment, Stage IIA Colon Cancer, Stage IIA Rectal Cancer, Stage IIB Colon Cancer, Stage IIB Rectal Cancer, Stage IIC Colon Cancer, Stage IIC Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions: Yoga Skills Training (YST), questionnaire administration, fatigue and depressive symptom assessment and management, psychological stress assessment, laboratory biomarker analysis, Attention Control; Behavioral · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome
Interventions: Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Biopsy Procedure, Biospecimen Collection, Colonoscopy, Nogapendekin Alfa, Placebo Administration, Questionnaire Administration; Biological · Procedure · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 13
States / cities: Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 10 more

Conditions: Colorectal Cancer
Interventions: laboratory biomarker analysis; Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 2,059 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Colorectal Cancer, Lung Cancer, Malignant Mesothelioma, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Thymoma and Thymic Carcinoma
Interventions: educational intervention, psychosocial assessment and care, quality-of-life assessment; Other · Procedure
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lung Non-Small Cell Carcinoma, Stage I Colorectal Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
Interventions: Quality-of-Life Assessment, Questionnaire Administration, Survivorship Care Plan, Telemedicine; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Central Nervous System Neoplasm, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Hodgkin Lymphoma, Malignant Bone Neoplasm, Malignant Brain Neoplasm, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Non-Hodgkin Lymphoma, Pathologic Stage I Cutaneous Melanoma AJCC v8, Pathologic Stage IA Cutaneous Melanoma AJCC v8, Pathologic Stage IB Cutaneous Melanoma AJCC v8, Pathologic Stage II Cutaneous Melanoma AJCC v8, Pathologic Stage IIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIC Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage I Cervical Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage I Differentiated Thyroid Gland Carcinoma AJCC v8, Stage I Ovarian Cancer AJCC v8, Stage I Thyroid Gland Medullary Carcinoma AJCC v8, Stage I Uterine Corpus Cancer AJCC v8, Stage IA Cervical Cancer AJCC v8, Stage IA Ovarian Cancer AJCC v8, Stage IA Uterine Corpus Cancer AJCC v8, Stage IA1 Cervical Cancer AJCC v8, Stage IA2 Cervical Cancer AJCC v8, Stage IB Cervical Cancer AJCC v8, Stage IB Ovarian Cancer AJCC v8, Stage IB Uterine Corpus Cancer AJCC v8, Stage IB1 Cervical Cancer AJCC v8, Stage IB2 Cervical Cancer AJCC v8, Stage IC Ovarian Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage II Differentiated Thyroid Gland Carcinoma AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Thyroid Gland Medullary Carcinoma AJCC v8, Stage II Uterine Corpus Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIA Ovarian Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIB Ovarian Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Differentiated Thyroid Gland Carcinoma AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Thyroid Gland Medullary Carcinoma AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8
Interventions: Medical Device Usage and Evaluation, Quality-of-Life Assessment, Survey Administration; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 39 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • Houston, Texas

Conditions: Stage I Colon Cancer, Stage I Rectal Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Colon Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIA Rectal Cancer, Stage IIB Colon Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIB Rectal Cancer, Stage IIC Colon Cancer, Stage IIC Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer
Interventions: educational intervention, questionnaire administration, quality-of-life assessment; Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Duarte, California

Search by objective public record fields.

Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer

TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

Genetic Mutations in Blood and Tissue Samples in Predicting Response to Treatment in Patients With Locally Advanced Rectal Cancer Undergoing Chemoradiation

Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial

Survivorship Care Plan in Promoting Physical Activity in Breast or Colorectal Cancer Survivors in Wisconsin

Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer

S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

Educational CD-ROM Compared With Standard Informed Consent for Patients With Colorectal Cancer or a Family History of Colorectal Cancer

Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers

Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Open-Label Phase IIb Efficacy Trial of Cancer Macrobeads Compared to Best Supportive Care in Colorectal Cancer Patients

Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients

S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride

Programs to Support You During Chemotherapy (Pro-You)

Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581

Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer

Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

Survivorship Care Planning in Patients With Colorectal or Non-Small Cell Lung Cancer